Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 10/20 | 0.50 |
| ▸ | ATP4B | P51164 | 10/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1846169 | 0.83 | PPARG (0.68) | PPARG | |
| SCHEMBL12520389 | 0.83 | PPARG (0.68) | PPARG | |
| SCHEMBL8717050 | 0.83 | RAB9A (0.48) | ALDH1A1TP53GAARAB9AKMT2A | |
| SCHEMBL6803223 | 0.82 | PPARG (0.45) | ALDH1A1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL1846171 | 0.82 | PPARG (0.55) | ATP4AATP4BALDH1A1TP53GAA | |
| SCHEMBL1746506 | 0.80 | KMT2A (0.57) | ALDH1A1TP53GAARAB9AKMT2A | |
| SCHEMBL6808372 | 0.79 | ATP4A (0.47) | ATP4AATP4BALDH1A1KMT2AMEN1 | |
| SCHEMBL6806605 | 0.79 | PPARG (0.46) | ATP4AATP4BALDH1A1MAPTPPARG | |
| SCHEMBL18674619 | 0.78 | RAB9A (0.60) | ATP4AATP4BALDH1A1TP53GAA | |
| SCHEMBL18674611 | 0.78 | RAB9A (0.57) | ALDH1A1TP53GAARAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6686475-B2 | THIAZOLIDINEDIONE DERIVATIVES HAVING HYPOGLYCAEMIC AND HYPOLIPIDAEMIC ACTIVITIES | BEECHAM GROUP P.L.C. (GB) | 2004-02-03 | — | — | US | disclosed |
| US-20030149054-A1 | Administering thiazolidinedione derivatives for therapy and prophylaxis of cardiovascular diseases or eating disorders in a human or non- human mammal | BEECHAM GROUP P.L.C. | 2003-08-07 | — | — | US | disclosed |
| US-20020049240-A1 | NOVEL COMPOUNDS | BEECHAM GROUP P.1.C. | 2002-04-25 | — | — | US | disclosed |
| US-6288095-B1 | ADMINISTERING 5-(4-(2-(N-METHYL-N-(2-PYRIDYL)AMINO)ETHOXY) BENZYL)-2,4-THIAZOLIDINEDIONE TO MAMMALS AS AN ANTIDIABETIC | BEECHAM GROUP P.L.C. (GB) | 2001-09-11 | — | — | US | disclosed |
| EP-0842925-A1 | Substituted thiazolidinedione derivatives | BEECHAM GROUP PLC (GB) | 1998-05-20 | — | — | EP | disclosed |
| US-5646169-A | ADMINISTERING SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVES TO HUMANS OR OTHER MAMMALS | BEECHAM GROUP P.L.C. (GB) | 1997-07-08 | — | — | US | disclosed |
| US-5521201-A | SUBSTITUTED-THIAZOLIDINEDIONE DERIVATIVES | BEECHAM GROUP P.L.C. | 1996-05-28 | — | — | US | disclosed |
| US-5232925-A | Treating hypertension | BEECHAM GROUP P.L.C. (GB) | 1993-08-03 | — | — | US | disclosed |
| US-5194443-A | Thiazolinediones, Hypoglycemic Agents, Antilipemic Agents | BEECHAM GROUP P.L.C. (GB) | 1993-03-16 | — | — | US | disclosed |
| US-5002953-A | Substituted Thiazolidinedione Derivatives | BEECHAM GROUP P.L.C. (GB) | 1991-03-26 | — | — | US | disclosed |
| EP-0306228-A1 | Substituted thiazolidinedione derivatives | BEECHAM GROUP PLC (GB) | 1989-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149054-A1 | Administering thiazolidinedione derivatives for therapy and prophylaxis of cardiovascular diseases or eating disorders in a human or non- human mammal | TYK2, FABP3, FABP4 | ATP4A 1793/4885ATP4B 3152/4885ALDH1A1 1150/4885 |
| US-20020049240-A1 | NOVEL COMPOUNDS | GRK1, GRK3, GRK7 | ATP4A 2743/4885ATP4B 3513/4885ALDH1A1 1255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.